Published in final edited form as:

Cancer Lett. 2017 August 10; 401: 11–19. doi:10.1016/j.canlet.2017.04.040.

Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells

Ranjani Lakshminarasimhan¹, Claudia Andreu-Vieyra^{1,2}, Kate Lawrenson^{5,6}, Christopher E. Duymich¹, Simon A. Gayther^{6,7}, Gangning Liang^{1,2,*}, and Peter A. Jones^{1,2,3,4,*}

¹Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

²Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

³Department of Biochemistry & Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

⁴Van Andel Research Institute, Grand Rapids, MI 49503, USA

⁵Department of Biomedical Sciences, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA

⁶Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite 290W, Los Angeles, CA, USA

⁷Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA

Abstract

The chromatin remodeler AT-Rich Interactive Domain 1A (ARID1A) is frequently mutated in ovarian clear cell carcinoma (OCCC) and endometriosis precursor lesions. Here, we show that knocking down ARID1A in an immortalized endometriosis cell line is sufficient to induce phenotypic changes indicative of neoplastic transformation as evidenced by higher efficiency of anchorage-independent growth, increased propensity to adhere to collagen, and greater capacity to invade basement membrane extract *in vitro*. ARID1A knockdown is associated with expression dysregulation of 99 target genes, and many of these expression changes are also observed in primary OCCC tissues. Further, pathway analysis indicates these genes fall within networks highly relevant to tumorigenesis including integrin and paxillin pathways. We demonstrate that the down-

*Corresponding authors: gliang@usc.edu (G.L.) and/or peter.jones@vai.org (P.A.J.), 1441 Eastlake Ave. NOR7344, Los Angeles, CA 90089, Tel:323-865-0470.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CONFLICT OF INTEREST

P.A. Jones is a paid consultant of Zymo Research Corporation, but otherwise the authors declare that they have no competing interests.

regulation of ARID1A does not markedly alter global chromatin accessibility or DNA methylation but unexpectedly, we find strong increases in the active H3K27ac mark in promoter regions and decreases of H3K27ac at potential enhancers. Taken together, these data provide evidence that ARID1A mutation can be an early stage event in the oncogenic transformation of endometriosis cells giving rise to OCCC.

Keywords

ARID1A; endometriosis; ovarian clear cell carcinoma; epigenetics; phenotypic transformation

1. INTRODUCTION

Epithelial ovarian cancer (EOC) has the highest mortality of all female reproductive malignancies in the United States [1]. Ovarian clear cell carcinoma (OCCC) accounts for 5–25% of EOCs and the advanced stages of OCCC have the worst patient outcomes of all EOC subtypes [2–4]. Lack of effective therapies and particularly resistance to conventional platinum-based chemotherapy contribute to the poor prognosis of late-stage OCCC [5, 6]. It is thought that OCCC arises from atypical endometriosis, however, a causal relationship between endometriosis and OCCC remains to be established [7, 8]. Thus, better understanding of the biological and functional processes governing the pathogenesis of OCCC is crucial to the development of more effective early detection tools and efficient treatment strategies.

Several studies have found that the SWI/SNF chromatin remodeler member AT-rich Interactive Domain 1A (ARID1A) is mutated in numerous cancer types and is the most commonly mutated gene in OCCC (46%–57%) and endometrioid carcinoma (26%–40%) [9–12]. OCCC shows the strongest association of any ovarian subtype with pre-existing endometriosis [7, 10, 13], and notably, mutation or loss of ARID1A expression has been noted in 15%–44% of endometriotic lesions [10, 14, 15]. Consequently, it has been proposed that ARID1A mutation might be an early event in the oncogenic transformation of endometriotic cells to OCCC [7, 12, 16].

Here, we investigate the potential functional role and the epigenetic impact of decreased ARID1A expression on oncogenesis by using an immortalized endometriosis cell line model, iEEC16 [17, 18], to evaluate for alterations of DNA methylation, nucleosome positioning, and histone modifications following ARID1A perturbation. Our studies reveal that the down-regulation of ARID1A expression in non-tumorigenic cells is sufficient to initiate tumorigenic transformation and dysregulation of gene expression through altered H3K27ac and targeted modulation of chromatin accessibility.

2. MATERIALS AND METHODS

2.1 Cell lines and reagents

IEEC16 was derived in-house from primary endometriosis sample and cultured in normal ovarian surface epithelial complete medium [17, 18]. Cell lines were characterized by STR-profiling and tested for mycoplasma at USC Norris Cancer Center. Lentiviral vector pLKO.1

with short-hairpin RNAs (shRNAs) targeting human *ARID1A* (clone IDs: TRCN0000059089, and TRCN0000059090) or a non-targeting scrambled sequence (Dharmacon) and packaging plasmids pCML1 and pMDG1 were used with Lipofectamine LTX Reagent with Plus (ThermoFisher) to generate virus. Cells were selected with 1 µg/ml puromycin.

2.2 Protein extraction and western blot analysis

Western blot was performed as described in [19]. Antibodies against ARID1A (Santa Cruz Biotechnology, sc-32761, 1:500, Dallas, TX) and β-ACTIN (Sigma, A2228, 1:2,000) were used.

2.3 ARID1A-KD and SCR *in-vitro* characterization

Anchorage-independent colony formation and cell adhesion assays were performed as described in [18, 20]. Cell invasion assay performed using Cultrex® BME cell invasion assay (R&D Systems) according to manufacturer's protocol.

2.4 NOME-seq assay

Nucleosome-occupancy and DNA methylome sequencing (NOME-seq) and data analyses were performed as previously described in [21, 22]. For locus-specific analysis, nuclei were treated with GpC Methyltransferase (NEB), genomic DNA was extracted and bisulfite-converted using EZ-DNA methylation kit (Zymo) and region specific primers (listed in Supplemental Table 1) were used to PCR-amplify the product which were then cloned and sequenced.

2.5 RNA extraction and analysis

Expression microarray analysis was performed and processed as previously described in [23] using BeadChipHumanHT12_V4 (Illumina). Pathway analysis was performed using Ingenuity Pathway Analysis (IPA, Qiagen). Oncomine™ (<https://www.oncomine.org/>) was used to mine publically available gene expression data (Qiagen). Quantitative PCR (qPCR) analysis was performed as described in [19]. Primers used in qPCR analysis are listed in Supplemental Table 1.

2.6 Chromatin immunoprecipitation sequencing (ChIP-seq), peak-calling, peak-annotation

ChIP-seq was performed as previously described [22]. ChIP assays were performed in replicates with scrambled control (SCR) cells; ChIP-assays in ARID1A-knockdown1 and ARID1A-knockdown2 samples were treated as biological replicates. The following antibodies from ActiveMotif were used: H3K4me3 (39160), H3K4me1 (39298), H3K27ac (39297), H3K27me3 (39155).

Unique ChIP-seq reads were mapped to hg19 using SeqMonk (<http://www.bioinformatics.babraham.ac.uk/projects/seqmonk>). Peaks were called on biological replicates using the model-based analysis of ChIP-seq (MACS) [24] algorithm with a p-value cutoff of 10^{-10} against input and only peaks common among the replicates were retained. Read count quantification, correcting for data store size and peak width, followed by log2 transformation was used to quantify peaks.

Active promoters were identified by the presence of H3K27ac and H3K4me3 within 2kb of an annotated TSS, inactive promoters were identified by H3K27me3 peaks overlapping TSS and H3K27ac peaks in regions >2kb away from TSS marked by the presence of H3K4me1 and absence of H3K4me3 were designated as enhancers [25–27]. A fold-difference of 1.5 between peak values in SCR and KD cells was used as a cut-off of change. Promoter peaks were annotated with overlapping gene. Enhancers often regulate multiple genes over considerable distances, however, studies have shown that enhancers affect the gene corresponding to the nearest TSS with a higher frequency than any other TSS in the genome [28, 29]. Therefore, putative enhancer peaks were annotated with the nearest gene within 200kb of the peak.

2.7 Data analysis and statistics

Data analysis and visualization was performed using the statistical language R. NOME-seq data analyses were performed as detailed in [22]. Two-tailed Student's t-test was performed and a p-value cut-off of 0.05 used for all statistical analysis unless mentioned otherwise. Bonferroni correction was applied when appropriate [30]. All data shown represent results of triplicated experiments (mean $\pm$ S.E.). The datasets supporting the results of this article are available at Gene Expression Omnibus (GEO) repository: [GSE86572](#), [GSE86810](#), [GSE97373](#).

3. RESULTS

3.1 Decreased ARID1A expression in an endometriosis cell line enhances colony formation capacity, cell adhesiveness, and invasiveness

To test whether ARID1A deficiency could be an early event in the transformation of endometriotic lesions to OCCC, we established stable knockdowns in the immortalized endometriosis cell line iEEC16. The down-regulation of ARID1A was confirmed at the mRNA and protein levels with independent shRNAs (KD1 and KD2) (Figure 1a). Endometriosis cells transduced with shRNA to knockdown *ARID1A* gene expression showed a statistically significant increase in anchorage-independent colony formation in soft agar relative to cells transduced with a non-targeting scrambled control (SCR) shRNA (p-value < 0.05) (Figure 1b). In addition, ARID1A knockdown cells displayed a tendency towards increased adhesion to collagen I and greater invasion through basement membrane extract (p-value < 0.05) (Figure 1c, and d). Thus, our cell line model supports our hypothesis that loss of ARID1A can instigate the acquisition of phenotypes associated with oncogenic transformation of endometriotic lesions.

3.2 Dysregulation of gene expression in ARID1A knockdowns mimic the expression changes in OCCC

To understand how reduction in ARID1A expression could contribute to direct functional changes in the progression from endometriosis to OCCC, we performed gene expression microarray analysis of the SCR and KD cell lines. We observed 99 genes with significant expression changes in both KD lines relative to the control (Fold Change (KD/SCR) > 1.4, p-value < 0.05) (Figure 2a, Supplemental table 2). Comparing these expression data with publicly available data on primary OCCC tumors obtained using the Oncomine™ data

portal, we observed a similar expression pattern in primary OCCC tissues for many of the genes dysregulated in our ARID1A KDs. These include gain of *GRPr* expression and loss of *SULF1* expression. *GRPr*, often upregulated in several solid tumor types, behaves as a growth factor contributing to tumor proliferation [31]. *SULF1*, frequently down-regulated in ovarian clear cell cancer, is known to promote cellular proliferation through growth factor signaling [32]. The top 20 genes with observed differential expression changes correlating with expression data from primary OCCC are summarized in Figure 2b.

Pathway analysis of the genes differentially expressed in the iEEC16 KD cell lines revealed that networks most significantly altered (p-value < 0.05) were either related to cancer or immune response (Figure 2c, Supplemental Figure 1a). Notable affected pathways included the integrin signaling pathway, which contributes to several cellular functions including cell adhesion and invasion, and the paxillin pathway, which is critical in mediating cell integrin signaling with p38, MAPK and JNK pathways, thereby altering cell proliferation and motility [33, 34]. Thus, gene expression alterations in these pathways might be responsible for the increased cell adhesion to collagen and invasion observed in ARID1A-KD cell lines (Figure 1c and d). Additionally, we identified genes that have been implicated in several gynecological malignancies including endometrial and ovarian cancer (Supplemental Figure 1b). Finally, many of the upstream-regulators of the differentially expressed genes, including *Cg*, *TNF*, *PDGF-BB*, *VEGF*, and *RASSF1*, have been previously linked to ovarian cancer [35–38] (Supplemental Figure 1c). Thus, these data show that genes exhibiting expression changes due to down-regulation of ARID1A in immortalized endometriosis cells function in pathways and networks critical to tumorigenesis and are frequently altered in primary ovarian tumors.

3.3 Global chromatin accessibility and DNA methylation signatures are maintained after decreased ARID1A

Due to its potential role as a chromatin remodeler protein, the decreased ARID1A levels may affect chromatin architecture and contribute to the observed phenotypic and gene expression alterations. We used the NOME-seq assay to simultaneously evaluate whole genome assessment of chromatin accessibility and DNA methylation [21, 22]. This method uses a GpC methyltransferase to methylate GpC sites present in DNA regions that are free of nucleosomes or other DNA binding proteins [39, 40]. Upon bisulfite conversion and sequencing, NOME-seq delivers a precise digital readout of both endogenous DNA methylation at the CpG sites and nucleosome occupancy or chromatin accessibility from the GpC sites.

Firstly, we interrogated chromatin accessibility and DNA methylation levels at aligned transcription start sites (TSSs) and CTCF insulator binding sites to attain a global overview of the effect of ARID1A down-regulation. Consistent with the literature, the majority of CpG Island (CGI) promoters were unmethylated and maintained a strong nucleosome depleted region (NDR) upstream of the TSS in both SCR and KD cell lines [21] (Figure 3, top panel). In contrast, most of the non-CGI promoters were methylated and NDRs were present in only a small subset of unmethylated non-CGI promoters (Figure 3, middle panel). Finally, the well-positioned and highly regular anti-correlative phasing of nucleosomes and

DNA methylation surrounding CTCF binding sites [21, 22] was also maintained in the ARID1A KD cell line (Figure 3, bottom panel). Thus, in spite of the reduction of ARID1A expression in iEEC16 cells and the resulting phenotypic and expression changes, the global chromatin accessibility or DNA methylation signatures at TSSs or CTCF insulator sites is retained (Figure 3).

3.4 ARID1A loss contributes to reconfiguration of chromatin through the widespread redistribution of H3K27ac and modest alteration of H3K27me3 at promoters

Since we did not detect global deregulation of accessibility or methylation at gene promoters and CTCF sites, we coupled our NOME-seq data with ChIP-seq data of various histone modifications to segment the genome into functional regions. Previous reports have indicated that H3K27ac and H3K27me3 marks might be involved in mediating ARID1A activity [41–44], therefore, we focused on the variations observed in these modifications.

While global levels of H3K27ac and H3K27me3 were only marginally altered in response to ARID1A KD in iEEC16 cells (Supplemental Figure 2), when the H3K27ac and H3K27me3 peaks were segmented into regulatory elements such as promoter and enhancers, a striking pattern emerged. The majority (>60%) of the H3K27ac promoter peaks showed greater read-count enrichment in the KD cells, while less than 0.5% of the promoter peaks were depleted in the KD cells (p-value < 2E-5) (Figure 4a). To understand the functional relevance of this altered H3K27ac distribution on the rest of the epigenetic landscape of iEEC16 cells, we examined the top 10% most altered H3K27ac promoter peaks, corresponding to 711 TSSs, by overlapping them with the NOME-seq data. While the promoters in both SCR and KD cells were unmethylated and most possessed an NDR upstream of the TSSs (Supplemental Figure 3a), a subset of the promoters showed a more pronounced region of accessibility in KD cells (Supplemental Figure 3a, marked by orange box) suggesting that ARID1A mediates targeted, rather than global, chromatin remodeling.

In contrast to H3K27ac at promoters, we found that only 15% of the H3K27me3 promoter peaks were altered in read count enrichment in ARID1A KDs; 8.5% showed greater enrichment and 6.5% showed depletion of this repressive mark in the KD cell line (Figure 4b). As with H3K27ac peaks, overlaying NOME-seq data on the H3K27me3 peaks showed no changes in DNA methylation (Supplemental Figure 3b; left two panels). However, a small subset of gene promoters losing H3K27me3 (Supplemental Figure 3b; right two panels, orange box) showed a modest gain in chromatin accessibility, while the promoters gaining H3K27me3 in the KD cell line displayed a decrease in accessibility in these regions (Supplemental Figure 3b; right two panels, below the dotted line). Thus, the downregulation of ARID1A in endometriosis cells reconfigures chromatin architecture through extensive increase of H3K27ac, and a modest, context-dependent alteration of H3K27me3 at gene promoters.

3.5 Down-regulation of ARID1A also contributes to the redistribution of H3K27ac mark at enhancers

In contrast to the increased enrichment of H3K27ac at most promoters, the majority of the altered enhancer peaks were reduced in H3K27ac upon the down-regulation of ARID1A

(Figure 4c). Nearly 24% of the enhancer peaks were decreased and less than 5% of the enhancer peaks were increased in H3K27ac enrichment in the KD cells (p-value < 2E-5) (Figure 4c).

Unlike promoters, enhancers do not have a defined start site with which to align NOME-seq data. Therefore, to generate chromatin accessibility and methylation maps of the enhancers (Supplemental Figure 3c) we aligned the top 10% of the most altered H3K27ac enhancer peaks with NDRs identified from NOME-seq data using a Hidden Markov Model (HMM) approach previously described [21, 22]. Nearly all of the enhancer peaks contained NDRs in SCR sample. Although no notable changes in DNA methylation were observed across the samples (Supplemental Figure 3c, left 2 panels), a subset of these enhancers lost NDRs in the KD (Supplemental Figure 3c, left 2 panels, marked by orange box), consistent with the loss of an active mark and suggesting that these regions undergo DNA methylation-independent chromatin remodeling upon ARID1A downregulation. These findings, coupled with those at promoters, suggest that ARID1A plays an important role in the distribution of H3K27ac histone marks and is driving changes to nucleosome positioning in these regions in a targeted and DNA methylation-independent manner.

3.6 The majority of differentially expressed genes are directly affected by epigenetic changes due to the decrease of ARID1A

Next, we sought to elucidate the ARID1A-mediated epigenetic regulation of the genes differentially expressed in ARID1A knockdown cells. We examined the chromatin accessibility data at all dysregulated gene promoters and putative enhancers (see Methods). By averaging the accessibility across the promoters, we found a small but significant correlative loss of chromatin accessibility consistent with gene expression at the 77 downregulated genes (Supplemental Figure 4a, 4c) and a correlative gain in accessibility at the 27 upregulated genes (Supplemental Figure 4b, 4c). Likewise, a trend of accessibility loss consistent with gene downregulation was noted at the 51 putative enhancers (Supplemental Figure 4d, 4f), and a trend of accessibility gain consistent with gene upregulation was noted at the 18 putative enhancers (Supplemental Figure 4e, 4f) though these changes were not statistically significant. Additionally, we observed that approximately 60% of genes changing in expression also had an accompanying change in histone marks at regulatory elements upon ARID1A KD (Figure 5, Supplemental Table 3). Among the down-regulated genes, nine promoters displayed loss of H3K27ac, nine promoters displayed gain of H3K27me3, and 39 genes showed loss of H3K27ac at a putative enhancers (Figure 5a), which correlate with expected chromatin-mediated gene downregulation. Conversely, among upregulated genes, 13 promoters saw gain of H3K27ac, nine promoters saw a loss of H3K27me3, and seven genes gained acetylation at a putative enhancers (Figure 5b), which likewise correlate with chromatin-mediated gene upregulation. Thus, these complementary active and repressive mark changes could be mediating the expression changes of the respective genes. The remaining genes with minimal to no histone marker changes could be due to secondary histone modification-independent effects, such as variations in the abundance of transcriptional factors in ARID1A KD cells.

As an illustration of ARID1A-driven epigenetic changes at promoters affecting gene expression, the *SVIL* and *ZNF583* promoters showed a gain of the active H3K27ac mark and both of these genes were increased in expression in the KD lines. In addition, the gain of H3K27ac mark at *SVIL* promoter was complemented with decreased H3K27me3 (Figure 6a). Overlaying ChIP-seq data with locus-specific NOME-seq data at the *ZNF583* CpG island promoter (Figure 6c), we observed an overall increase in accessibility directly upstream of the TSSs along with a gain of H3K27ac peak in the KD cells (Figure 6c, highlighted with blue boxes). Furthermore, the nucleosomes were less consistently maintained in the KD cell line indicating weaker positioning relative to the SCR cell line. Thus, ARID1A may be required for the down-regulation of *ZNF583* expression by maintaining strongly positioned nucleosomes at its promoter. In accordance meanwhile, the promoters of downregulated genes *SULF1* and *CCL2* showed H3K27ac depletion in the KD cells, and the *SULF1* promoter was also enriched for the repressive H3K27me3 mark (Figure 6b).

Similarly modulation of active marks at putative enhancers also seem to mediate gene expression changes. For example, enhancer peaks corresponding to the upregulated genes *LRP3* and *JAM3* displayed an increase in the enrichment of H3K27ac in the KD cells (Figure 6d), while the corresponding enhancers to the downregulated genes *TLE* and *NTF3* were strongly depleted in the KD (Figure 6e). *NTF3* notably was downregulated in both the iEEC16 cell line (Supplemental Table 2) and in primary OCCC expression data from Oncomine™ (Figure 2b, top panel). Locus-specific NOME-seq analysis of the *NTF3* enhancer revealed a stark loss in accessibility in the KD cells (marked by a green line in Figure 6f), which could result in the decreased *NTF3* gene expression observed in the KD cell lines. Thus, ARID1A could be required to keep the chromatin open and accessible in the enhancer for proper transcription and expression of *NTF3*.

In summary, nearly 60% of the genes differentially expressed by ARID1A KDs were also correspondingly altered in active and repressive histone marks in promoters and/or enhancers (Figure 5a, and 5b). Closer inspection of some of these regulatory elements showed stark changes in chromatin accessibility complementing the histone modification and gene expression variations (Figure 6c, and 6f). Taken together, these data suggest that gene expression changes resulting from loss of ARID1A is partly mediated by DNA methylation-independent modulation of histone modifications and chromatin accessibility.

4. DISCUSSION

OCCC is an aggressive subtype of EOC that is tightly correlated with preexisting endometriosis. *ARID1A* gene mutations and loss of expression are common to both OCCC and endometriosis. Therefore, in this study, we characterized the effects of ARID1A down-regulation in endometriosis cells to identify the phenotypic and molecular changes that can potentially contribute to the malignant transformation of endometriotic cells to OCCC. First, we observed higher efficiency of anchorage-independent growth, increased cell propensity to adhere to collagen, and increased invasion of basement membrane *in vitro*. Anchorage-independent growth is known to correlate with neoplastic growth and considered to be a barometer of tumorigenicity [45, 46]. Additionally, cell adhesion to collagen can be crucial

for cancer cell signaling, invasion, and metastasis [47, 48]. Thus, the phenotypic alterations due to ARID1A loss in the non-tumorigenic iEEC16 cell line suggest that ARID1A mutation could be a necessary step in the malignant transformation of endometriotic cells.

Gene expression analysis revealed that nearly 100 genes were altered in expression upon down-regulation of ARID1A. A majority of these expression changes were accompanied by alterations in histone modification. However, gene transcription is controlled by the availability of regulatory factors and transcriptional machinery, along with the permissiveness of regulatory elements (marked by active histone marks). A recent study suggested that loss of ARID1A can restrict promoter accessibility to transcription factors, thereby affecting histone modifications, and in turn effecting gene expression and phenotypic changes [43]. It has also been noted that SWI/SNF complexes can compensate for the loss of ARID1A by incorporating homologs such as ARID1B [43, 49]. These secondary mechanisms may also contribute to expression changes, especially of the genes for which minimal to no histone modification alterations are evident.

One of the key findings from this work is that ARID1A mediated effects on chromatin structure are context- and locus-dependent, rather than global. This localized effect may be due to the various binding partners at these regulatory elements. These data are supported by a recent study investigating the consequences of ARID1A loss in colon cancer [44], which found that ARID1A is necessary for the proper steering of SWI/SNF complexes to its specific genomic targets. Particularly, the group noted minimal alteration of H3K27ac enrichment at promoters and a significant diminishing of H3K27ac levels at enhancers in the absence of ARID1A correlating with reduced mRNA levels of the nearest genes. ARID1A is known to function at both promoters and enhancers, and SWI/SNF complex members have been found to interact with both histone acetyltransferases (HATs) and histone deacetylases (HDACs) [50–52]. Accordingly, we noted that over 60% of promoters and nearly 25% of enhancers were altered in H3K27ac enrichment upon loss of ARID1A, and some of these histone changes translated to stark corresponding alterations in chromatin accessibility, and likely gene expression, as the majority of the differentially expressed genes showed correlative histone mark alterations. Furthermore, we noted substantial chromatin accessibility modulation in a locus specific manner. Thus, we find ARID1A has a targeted, rather than global, effect on the epigenome and transcriptional regulation. Together, these findings highlight the context-dependent role of chromatin remodelers in normal and cancerous tissue.

In summary, our findings demonstrate that reduced ARID1A alters the distribution of histone modifications, modulates the permissiveness of some regulatory elements, affects gene expression changes, and finally contributes to cellular transformation. It has been long speculated that endometriosis could be a precursor to OCCC [7, 15], and our work provides evidence that loss of ARID1A in non-tumorigenic endometriosis cells is sufficient for the induction of epigenetic, molecular, and phenotypic alterations indicative of potentially oncogenic transformation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We would like to thank Dr. Charles Nicolet and the USC Epigenome Center for preparing DNA sequencing libraries, and generating sequencing data. We acknowledge Drs. Fides Lay, Elinne Becket, and Jessica Charlet for helpful discussion. Computation was performed at the USC High Performance Computing and Communications Center (<http://www.usc.edu/hpcc/>).

Funding: This work was supported by the NIH National Cancer Institute RO1CA082422 (PAJ), R01CA083867 (PAJ and GL), and R00CA184415 (KL) and by the Vicky Joseph Cancer Research Fund (GL).

References

1. U.S. Cancer Statistics Working Group. United States Cancer Statistics Incidence and Mortality Webbased Report Internet cited Jun 6 Available from <https://nccdcgov.uscs>. SRC - GoogleScholar; 2015. p. 1999-2012.
2. Helleman J, Jansen MPH, Span PN, van Staveren IL, Massuger LFAG, Meijer-van Gelder ME, Sweep FCGJ, Ewing PC, van der Burg MEL, Stoter G, Nooter K, Berns EMJJ. Molecular profiling of platinum resistant ovarian cancer. *International Journal of Cancer*. 2005; 118:1963–1971.
3. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. *Cancer Science*. 2008; 99:653–658. [PubMed: 18377417]
4. Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. *American Journal of Obstetrics and Gynecology*. 2015; 213:262–267. [PubMed: 25818671]
5. Anglesio MS, Carey MS, Köbel M, MacKay H, Huntsman DG. Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010. *Gynecologic Oncology*. 2011; 121:407–415. [PubMed: 21276610]
6. Matsuzaki S, Yoshino K, Ueda Y, Matsuzaki S, Kakuda M, Okazawa A, Egawa-Takata T, Kobayashi E, Kimura T. Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives. *Cancer Cell International*. 2015; 15
7. Ayhan A, Mao T-L, Seckin T, Wu C-H, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, Shih I-M. Loss of ARID1A Expression Is an Early Molecular Event in Tumor Progression From Ovarian Endometriotic Cyst to Clear Cell and Endometrioid Carcinoma. *International Journal of Gynecological Cancer*. 2012; 22:1310–1315. [PubMed: 22976498]
8. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. *Hum Pathol*. 2011; 42:918–931. [PubMed: 21683865]
9. Jones S, Wang TL, Shih IM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma. *Science*. 2010; 330:228–231. [PubMed: 20826764]
10. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJM, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih I-M, Mes-Masson A-M, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG. ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas. *New England Journal of Medicine*. 2010; 363:1532–1543. [PubMed: 20942669]
11. Guan B, Mao T-L, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, Chen E, Jeng Y-M, Wang T-L, Shih I-M. Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma. *The American Journal of Surgical Pathology*. 2011; 35:625–632. [PubMed: 21412130]

12. Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, Gilks B, Huntsman DG. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. *The Journal of Pathology*. 2011; 224:328–333. [PubMed: 21590771]
13. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *The Lancet Oncology*. 2012; 13:385–394. [PubMed: 22361336]
14. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. *Modern Pathology*. 2011; 25:615–624. [PubMed: 22157930]
15. Xiao W, Awadallah A, Xin W. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma. *Int J Clin Exp Pathol*. 2012; 5:642–650. [PubMed: 22977660]
16. Guan B, Wang TL, Shih IM. ARID1A, a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers. *Cancer Research*. 2011; 71:6718–6727. [PubMed: 21900401]
17. Brueggmann D, Templeman C, Starzinski-Powitz A, Rao NP, Gayther SA, Lawrenson K. Novel three-dimensional in vitro models of ovarian endometriosis. *Journal of Ovarian Research*. 2014; 7:17. [PubMed: 24502583]
18. Lawrenson K, Lee N, Torres HAM, Lee JM, Brueggmann D, Rao PN, Noushmehr H, Gayther SA. Src as a novel therapeutic target for endometriosis. *Gynecologic Oncology*. 2014; 135:100–107. [PubMed: 24972189]
19. Duymich CE, Charlet J, Yang X, Jones PA, Liang G. DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in somatic cells. *Nature Communications*. 2016; 7:11453.
20. Spisák S, Lawrenson K, Fu Y, Csabai I, Cottman RT, Seo JH, Haiman C, Han Y, Lenci R, Li Q, Tisza V, Szállási Z, Herbert ZT, Chabot M, Pomerantz M, Solymosi N, Gayther SA, Joung JK, Freedman ML, Consortium G-OE. CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants. *Nat Med*. 2015; 21:1357–1363. [PubMed: 26398868]
21. Kelly TK, Liu Y, Lay FD, Liang G, Berman BP, Jones PA. Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. *Genome Research*. 2012; 22:2497–2506. [PubMed: 22960375]
22. Lay FD, Liu Y, Kelly TK, Witt H, Farnham PJ, Jones PA, Berman BP. The role of DNA methylation in directing the functional organization of the cancer epigenome. *Genome Research*. 2015; 25:467–477. [PubMed: 25747664]
23. Yang X, Han H, De Carvalho Daniel D, Lay Fides D, Jones Peter A, Liang G. Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer. *Cancer Cell*. 2014; 26:577–590. [PubMed: 25263941]
24. Zhang Y, Liu T, Meyer CA, Eeckhoutte J, Johnson DS, Bernstein BE, Nussbaum C, Myers RM, Brown M, Li W, Liu XS. Model-based Analysis of ChIP-Seq (MACS). *Genome Biol*. 2008; 9:R137. [PubMed: 18798982]
25. Calo E, Wysocka J. Modification of Enhancer Chromatin: What, How, and Why? *Molecular Cell*. 2013; 49:825–837. [PubMed: 23473601]
26. Charlet J, Duymich Christopher E, Lay Fides D, Mundbjerg K, Dalsgaard Sørensen K, Liang G, Jones Peter A. Bivalent Regions of Cytosine Methylation and H3K27 Acetylation Suggest an Active Role for DNA Methylation at Enhancers. *Molecular Cell*. 2016; 62:422–431. [PubMed: 27153539]
27. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, Alvarez P, Brockman W, Kim T-K, Koche RP, Lee W, Mendenhall E, O'Donovan A, Presser A, Russ C, Xie X, Meissner A, Wernig M, Jaenisch R, Nusbaum C, Lander ES, Bernstein BE. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. *Nature*. 2007; 448:553–560. [PubMed: 17603471]

28. Li G, Ruan X, Auerbach Raymond K, Sandhu Kuljeet S, Zheng M, Wang P, Poh Huay M, Goh Y, Lim J, Zhang J, Sim Hui S, Peh Su Q, Mulawadi Fabianus H, Ong Chin T, Orlov Yuriy L, Hong S, Zhang Z, Landt S, Raha D, Euskirchen G, Wei C-L, Ge W, Wang H, Davis C, Fisher-Aylor KI, Mortazavi A, Gerstein M, Gingeras T, Wold B, Sun Y, Fullwood Melissa J, Cheung E, Liu E, Sung W-K, Snyder M, Ruan Y. Extensive Promoter-Centered Chromatin Interactions Provide a Topological Basis for Transcription Regulation. *Cell*. 2012; 148:84–98. [PubMed: 22265404]
29. Yao L, Shen H, Laird PW, Farnham PJ, Berman BP. Inferring regulatory element landscapes and transcription factor networks from cancer methylomes. *Genome Biol*. 2015; 16
30. Dunn O. MULTIPLE COMPARISONS AMONG MEANS. *JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION*. 1961; 56:52–64.
31. Cornelio DB, Roesler R, Schwartzmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. *Ann Oncol*. 2007; 18:1457–1466. [PubMed: 17351255]
32. He X, Khurana A, Roy D, Kaufmann S, Shridhar V. Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer. *International Journal of Cancer*. 2014; 135:1783–1789. [PubMed: 24596063]
33. Hildebrand JD, Schaller MD, Parsons JT. Paxillin, a tyrosine phosphorylated focal adhesion-associated protein binds to the carboxyl terminal domain of focal adhesion kinase. *Molecular Biology of the Cell*. 1995; 6:637–647. [PubMed: 7579684]
34. Kumar CC. Signaling by integrin receptors. *Oncogene*. 1998; 17:1365–1373. [PubMed: 9779984]
35. Fu L, Zhang S. RASSF1A promotes apoptosis and suppresses the proliferation of ovarian cancer cells. *International Journal of Molecular Medicine*. 2014
36. Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, Jeng MH, Sledge GW. PDGF BB induces VEGF secretion in ovarian cancer. *Cancer Biology & Therapy*. 2007; 6:1951–1959. [PubMed: 18075302]
37. Tashiro H, Katabuchi H, Begum M, Li X, Nitta M, Ohtake H, Okamura H. Roles of luteinizing hormone/chorionic gonadotropin receptor in anchorage-dependent and -independent growth in human ovarian surface epithelial cell lines. *Cancer Science*. 2003; 94:953–959. [PubMed: 14611671]
38. Gupta M, Babic A, Beck AH, Terry K. TNF- α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis? *Human Pathology*. 2016; 54:82–91. [PubMed: 27068525]
39. Taberlay, Philippa C., Kelly, Theresa K., Liu, C-C., You, Jueng S., De Carvalho, Daniel D., Miranda, Tina B., Zhou, Xianghong J., Liang, G., Jones, Peter A. Polycomb-Repressed Genes Have Permissive Enhancers that Initiate Reprogramming. *Cell*. 2011; 147:1283–1294. [PubMed: 22153073]
40. Wolff EM, Byun H-M, Han HF, Sharma S, Nichols PW, Siegmund KD, Yang AS, Jones PA, Liang G. Hypomethylation of a LINE-1 Promoter Activates an Alternate Transcript of the MET Oncogene in Bladders with Cancer. *PLoS Genetics*. 2010; 6:e1000917. [PubMed: 20421991]
41. Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih I-M, Conejo-Garcia JR, Speicher DW, Zhang R. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. *Nature Medicine*. 2015
42. Kim KH, Kim W, Howard TP, Vazquez F, Tsherniak A, Wu JN, Wang W, Haswell JR, Walensky LD, Hahn WC, Orkin SH, Roberts CWM. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. *Nature Medicine*. 2015; 21:1491–1496.
43. Sun X, Chuang J-C, Kanchwala M, Wu L, Celen C, Li L, Liang H, Zhang S, Maples T, Nguyen Liem H, Wang Sam C, Signer Robert AJ, Sorouri M, Nassour I, Liu X, Xu J, Wu M, Zhao Y, Kuo Y-C, Wang Z, Xing C, Zhu H. Suppression of the SWI/SNF Component Arid1a Promotes Mammalian Regeneration. *Cell Stem Cell*. 2016; 18:456–466. [PubMed: 27044474]
44. Mathur R, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, Park PJ, Shivdasani RA, Roberts CW. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. *Nat Genet*. 2016
45. Freedman V. Cellular tumorigenicity in nude mice: Correlation with cell growth in semi-solid medium. *Cell*. 1974; 3:355–359. [PubMed: 4442124]

46. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatz M, Murphy S, Nevins JR. Anchorage-independent cell growth signature identifies tumors with metastatic potential. *Oncogene*. 2009; 28:2796–2805. [PubMed: 19483725]
47. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. *Nature Reviews Cancer*. 2004; 4:118–132. [PubMed: 14964308]
48. Chen Y, Lu B, Yang Q, Fearn C, Yates JR, Lee JD. Combined Integrin Phosphoproteomic Analyses and Small Interfering RNA-Based Functional Screening Identify Key Regulators for Cancer Cell Adhesion and Migration. *Cancer Research*. 2009; 69:3713–3720. [PubMed: 19351860]
49. Raab JR, Resnick S, Magnuson T. Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes. *PLoS Genet*. 2015; 11:e1005748. [PubMed: 26716708]
50. Kim M, Lu F, Zhang Y. Loss of HDAC-Mediated Repression and Gain of NF- κ B Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer. *Cell Rep*. 2016; 17:275–288. [PubMed: 27681437]
51. Zhang HS, Gavin M, Dahiya A, Postigo AA, Ma D, Luo RX, Harbour JW, Dean DC. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. *Cell*. 2000; 101:79–89. [PubMed: 10778858]
52. Chatterjee N, Sinha D, Lemma-Dechassa M, Tan S, Shogren-Knaak MA, Bartholomew B. Histone H3 tail acetylation modulates ATP-dependent remodeling through multiple mechanisms. *Nucleic Acids Res*. 2011; 39:8378–8391. [PubMed: 21749977]
53. Hendrix ND. Fibroblast Growth Factor 9 Has Oncogenic Activity and Is a Downstream Target of Wnt Signaling in Ovarian Endometrioid Adenocarcinomas. *Cancer Research*. 2006; 66:1354–1362. [PubMed: 16452189]

Highlights

- ARID1A down-regulation in endometriosis cells induces phenotype alterations that could contribute to malignant transformation.
- Many genes with altered expression in ARID1A knockdown endometriosis cells are similarly dysregulated in primary OCCC.
- ARID1A knockdown initiates epigenetic reprogramming as evidenced by striking redistribution of H3K27ac; this is accompanied by targeted changes in chromatin accessibility.

Figure 1. ARID1A KD lines established in iEEC16 show phenotypic alterations

Two ARID1A knockdown (KD1 and KD2) and one scrambled control (SCR) lines were established in iEEC16. (a) Bar-graph of *ARID1A* mRNA levels (n=3, p-value < 0.05) along with representative western blot image of ARID1A protein and beta-Actin loading control, bar-graph quantifying (b) the number of colonies grown in soft agar along with representative phase-contrast microscopy images, (c.) cell adhesion to collagen measurement (n=3, p-value < 0.05), and (d) fluorescence measurement of cells that successfully invaded through BME *in-vitro* (n=3, p-value < 0.05).

Figure 3. NOME-seq reveals that the majority of the genome is unperturbed by down-regulation of ARID1A

Heatmaps of NOME-seq methylation levels (CG methylation for “DNA methylation” and GC methylation for “Accessibility”) were aligned to the center of CGI TSS (N=20145), non-CGI TSS (N=23594) or CTCF binding sites (N=13506), extended by ± 1 kb. CpG methylation is plotted on a scale of 0 (blue) to 100 (yellow) and GpC methylation is plotted on a scale of 0 (white) to 100 (green). TSS or CTCF sites were hierarchically clustered based on the accessibility within ± 250 bp of the site.

Figure 4. Down-regulation of ARD1A promotes re-distribution of H3K27ac and H4K27me3
 (a–c) H3K27ac and H3K27me3 data from ARD1A KD and SCR cell lines were used. Pie-charts summarize histone peaks with increased read-count enrichment by 1.5-fold (“increased”), decreased read-count enrichment by 1.5-fold (“decreased”), or unchanged in read-count enrichment (“unchanged”) in the KD cells relative to SCR cells. Box-plots quantify log2 of read-count enrichment in the “increased” or “decreased” peaks. (a) H3K27ac peaks at gene promoters (n=6910) (b) H3K27me3 peaks at gene promoters (n=3019). (c) H3K27ac enhancer peaks (n=33627). (p-value < 2E-5).

Figure 5. A subset of the differentially expressed genes are epigenetically regulated by ARID1A
 (a) Venn-diagrams of down-regulated genes showing any loss in H3K27ac (at promoters or enhancers) or gain in H3K27me3 at gene promoters. (b) Venn-diagrams of upregulated genes showing any gain in H3K27ac (at promoters or enhancers) or loss of H3K27me3 at gene promoters.

Figure 6. Down-regulation of ARID1A contributes to both gain and loss of regulatory elements
 IGV browser view of gene promoters and enhancers (a, b, d, e). The first track shows the gene or genomic region, followed by a track denoting CGIs. Next, wiggle plots of H3K27ac ChIP-seq enrichment in SCR cells and ARID1A KD cells are shown, finally wiggle plots of H3K27me3 ChIP-seq enrichment data are displayed. (c, f) Unfilled circles are unmethylated GpC sites, teal filled circles denote methylated (accessible) GpC sites. Nucleosome is indicated with a pink bar representing region of inaccessibility greater than 146bp. TSS is marked by black arrow and center of enhancer peak is denoted by a green line. (a) *SVIL* and *ZNF583*, are gaining acetylation peak at their respective promoters, and (b) *SULF1* and *CCL2*, are losing the H3K27ac mark at the promoter. (c) The gain in H3K27ac at the *ZNF583* promoter is accompanied by increased chromatin accessibility upstream of the 3 TSSs. (d) *LRP3* and *JAM3*, gain acetylation peak at their respective gene body enhancer, and (e) *TLE4* and *NTF3* lose the active enhancer element in the gene body. (f) The decrease in H3K27ac at the enhancer of *NTF3* is accompanied by decreased chromatin accessibility downstream of the enhancer peak center.